JP2019523008A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019523008A5 JP2019523008A5 JP2019504923A JP2019504923A JP2019523008A5 JP 2019523008 A5 JP2019523008 A5 JP 2019523008A5 JP 2019504923 A JP2019504923 A JP 2019504923A JP 2019504923 A JP2019504923 A JP 2019504923A JP 2019523008 A5 JP2019523008 A5 JP 2019523008A5
- Authority
- JP
- Japan
- Prior art keywords
- recombinant virus
- recombinant
- virus
- administering
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022129037A JP2022163182A (ja) | 2016-07-29 | 2022-08-12 | 腫瘍溶解性ウイルスによるＰＴＥＮ－Ｌｏｎｇの発現 |
| JP2024096293A JP2024123088A (ja) | 2016-07-29 | 2024-06-13 | 腫瘍溶解性ウイルスによるＰＴＥＮ－Ｌｏｎｇの発現 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662368822P | 2016-07-29 | 2016-07-29 | |
| US62/368,822 | 2016-07-29 | ||
| US201762479671P | 2017-03-31 | 2017-03-31 | |
| US62/479,671 | 2017-03-31 | ||
| PCT/US2017/044683 WO2018023114A1 (en) | 2016-07-29 | 2017-07-31 | Expression of pten-long with ocolytic viruses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022129037A Division JP2022163182A (ja) | 2016-07-29 | 2022-08-12 | 腫瘍溶解性ウイルスによるＰＴＥＮ－Ｌｏｎｇの発現 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019523008A JP2019523008A (ja) | 2019-08-22 |
| JP2019523008A5 true JP2019523008A5 (enExample) | 2020-09-10 |
| JP7638061B2 JP7638061B2 (ja) | 2025-03-03 |
Family
ID=61016870
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019504923A Active JP7638061B2 (ja) | 2016-07-29 | 2017-07-31 | 腫瘍溶解性ウイルスによるＰＴＥＮ－Ｌｏｎｇの発現 |
| JP2022129037A Pending JP2022163182A (ja) | 2016-07-29 | 2022-08-12 | 腫瘍溶解性ウイルスによるＰＴＥＮ－Ｌｏｎｇの発現 |
| JP2024096293A Pending JP2024123088A (ja) | 2016-07-29 | 2024-06-13 | 腫瘍溶解性ウイルスによるＰＴＥＮ－Ｌｏｎｇの発現 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022129037A Pending JP2022163182A (ja) | 2016-07-29 | 2022-08-12 | 腫瘍溶解性ウイルスによるＰＴＥＮ－Ｌｏｎｇの発現 |
| JP2024096293A Pending JP2024123088A (ja) | 2016-07-29 | 2024-06-13 | 腫瘍溶解性ウイルスによるＰＴＥＮ－Ｌｏｎｇの発現 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20200085890A1 (enExample) |
| EP (2) | EP4403229A3 (enExample) |
| JP (3) | JP7638061B2 (enExample) |
| KR (1) | KR102780496B1 (enExample) |
| CN (1) | CN110087662A (enExample) |
| AU (1) | AU2017301901B2 (enExample) |
| SG (1) | SG11201900815UA (enExample) |
| WO (1) | WO2018023114A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
| US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
| CN105939767B (zh) | 2014-01-08 | 2018-04-06 | 弗洛设计声能学公司 | 具有双声电泳腔的声电泳装置 |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| EP3529347A1 (en) | 2016-10-19 | 2019-08-28 | Flodesign Sonics, Inc. | Affinity cell extraction by acoustics |
| SG11202101581RA (en) * | 2017-08-09 | 2021-03-30 | Ohio State Innovation Foundation | Oncolytic virus carrying e-cadherin and uses thereof |
| WO2019102268A1 (en) | 2017-11-22 | 2019-05-31 | Mesoblast International Sarl | Cellular compositions and methods of treatment i |
| CN114900773A (zh) | 2017-12-14 | 2022-08-12 | 弗洛设计声能学公司 | 声泳系统及其操作方法、控制声换能器及声学系统的方法 |
| CN108484780A (zh) * | 2018-04-16 | 2018-09-04 | 河南大学 | 一种融合蛋白PTEN-L-p53及其应用 |
| US20220169997A1 (en) * | 2019-04-12 | 2022-06-02 | Therapten Biosciences Inc. | Compositions and methods to manufacture tumor suppressor fusions |
| KR20220038485A (ko) * | 2019-08-05 | 2022-03-28 | 메조블라스트 인터내셔널 에스에이알엘 | 바이러스 벡터를 포함하는 세포 조성물 및 치료 방법 |
| CN111763260B (zh) * | 2020-06-11 | 2022-03-29 | 四川大学华西医院 | 一种PTEN-Long多克隆抗体及其制备方法和用途 |
| WO2024163335A2 (en) * | 2023-01-30 | 2024-08-08 | The Board Of Regents Of The University Of Texas System | Pten gene therapy vectors and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1601438A (enExample) | 1968-10-17 | 1970-08-24 | ||
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US6261834B1 (en) | 1991-11-08 | 2001-07-17 | Research Corporation Technologies, Inc. | Vector for gene therapy |
| GB9801930D0 (en) * | 1998-01-29 | 1998-03-25 | Univ London | Mutant herpes simplex viruses and uses thereof |
| US20060147420A1 (en) * | 2004-03-10 | 2006-07-06 | Juan Fueyo | Oncolytic adenovirus armed with therapeutic genes |
| WO2005107474A2 (en) | 2004-04-30 | 2005-11-17 | Introgen Therapeutics, Inc. | Oncolytic adenovirus armed with therapeutic genes |
| US8658778B2 (en) * | 2005-03-09 | 2014-02-25 | Board Of Regents, The University Of Texas System | hTMC promoter and vectors for the tumor-selective and high-efficient expression of cancer therapeutic genes |
| US8450106B2 (en) * | 2007-10-17 | 2013-05-28 | The Ohio State University Research Foundation | Oncolytic virus |
| BRPI1005951A2 (pt) * | 2009-02-17 | 2016-10-11 | Univ Columbia | polipeptídeo de fosfatase humana isolada e homológo de tensina longo (pten-longo), composição farmacêutica, método para tratamento de um tumor sólido em um indivíduo, método para inibir crescimento de um tumor sólido em um indivíduo, método para inibir angiogênese em um tumor sólido em um indivíduo, método para induzir apoptose de uma célula vascular epitélial de um vaso sanguíneo em um tumor sólido em um indivíduo, método para tratar um tumor sólido em um indivíduo, polipeptídeo de fósfatase humana e homólogo de tensina longo (pten-longo), pten-longo ou um fragmento desteou o análogo deste, composição, ácido nuclêico isolado que codifica um polipeptídeode fosfatase humana e homólogo de tensina longo (pten-longo), vetor de expressão, célula transformada capaz de expressar polipeptídeo de fosfatase humana e homológo de tensina longo (pten-longo), célula hospedeira capaz de expressar polipeptídeo de fosfatase humana e humológo de tensina longo (pten-longo), processo, molécula de ácido nuclêico isolada, anticorpo isolado, fragmento de anticorpo e fragmento de peptídeo da seq id no: 1 ou seq id no: 5 |
| MX2012009565A (es) * | 2010-02-17 | 2014-02-27 | Univ Columbia | Uso de la secuencia lider de pten largo para la liberacion de moleculas transmembrana. |
| EP2563919B1 (en) * | 2010-04-26 | 2018-06-13 | Green Cross Corporation | Tumor-specific promoter and oncolytic virus vector comprising the same |
| EP2494978A1 (en) * | 2011-03-03 | 2012-09-05 | Bundesrepublik Deutschland, Letztvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts | Enhanced tumor therapy by tumor stem cell targeted oncolytic viruses |
| US9863935B2 (en) * | 2012-05-08 | 2018-01-09 | H. Lee Moffitt Cancer And Research Institute, Inc. | Predictive biomarkers for CTLA-4 blockade therapy and for PD-1 blockade therapy |
| US20160060652A1 (en) | 2013-03-13 | 2016-03-03 | Lapian's Corp | Microvesicle and method for producing the same |
| DK3184641T3 (da) * | 2013-10-28 | 2020-08-03 | Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education | Onkolytisk hsv-vektor |
| GB201408297D0 (en) * | 2014-05-12 | 2014-06-25 | Virttu Biolog Ltd | Treatment of cancer |
-
2017
- 2017-07-31 KR KR1020197005487A patent/KR102780496B1/ko active Active
- 2017-07-31 JP JP2019504923A patent/JP7638061B2/ja active Active
- 2017-07-31 EP EP24176375.4A patent/EP4403229A3/en active Pending
- 2017-07-31 WO PCT/US2017/044683 patent/WO2018023114A1/en not_active Ceased
- 2017-07-31 EP EP17835414.8A patent/EP3490574B8/en active Active
- 2017-07-31 CN CN201780059869.5A patent/CN110087662A/zh active Pending
- 2017-07-31 AU AU2017301901A patent/AU2017301901B2/en active Active
- 2017-07-31 US US16/321,777 patent/US20200085890A1/en active Pending
- 2017-07-31 SG SG11201900815UA patent/SG11201900815UA/en unknown
-
2022
- 2022-08-12 JP JP2022129037A patent/JP2022163182A/ja active Pending
-
2023
- 2023-01-06 US US18/151,195 patent/US20230338443A1/en not_active Abandoned
-
2024
- 2024-06-13 JP JP2024096293A patent/JP2024123088A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Peter et al. | Oncolytic adenovirus in cancer immunotherapy | |
| Webb et al. | Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response | |
| Sivanandam et al. | Oncolytic viruses and immune checkpoint inhibition: the best of both worlds | |
| JP2022163182A5 (enExample) | ||
| Sánchez et al. | African swine fever virus controls the host transcription and cellular machinery of protein synthesis | |
| Bridle et al. | Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8+ T-cell responses to anticancer vaccines | |
| WO2018073393A3 (en) | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy | |
| SG10201901482XA (en) | Oncolytic adenovirus encoding a b7 protein | |
| NZ749586A (en) | Expression of nkg2d activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells | |
| Wang et al. | Survivin promoter-regulated oncolytic adenovirus with Hsp70 gene exerts effective antitumor efficacy in gastric cancer immunotherapy | |
| JP2018500006A5 (enExample) | ||
| MD4748B1 (ro) | Terapii imunooncolitice | |
| WO2011119925A3 (en) | Synthetic herpes simplex viruses for treatment of cancers | |
| Toribio et al. | Inhibition of host translation by virus infection in vivo | |
| Tian et al. | Oncolytic Newcastle disease virus expressing the co-stimulator OX40L as immunopotentiator for colorectal cancer therapy | |
| JP2014523236A (ja) | 腫瘍溶解性強化Ｂ型ヒトアデノウイルスＡｄ１１突然変異体の構築とその応用 | |
| RU2018101722A (ru) | Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии | |
| MX2021007860A (es) | Poxvirux deficiente en m2. | |
| Xu et al. | Apolipoprotein A1-encoding recombinant adenovirus remodels cholesterol metabolism in tumors and the tumor microenvironment to inhibit hepatocellular carcinoma | |
| JP2018517419A5 (enExample) | ||
| CN103740756B (zh) | 一种可调控删除的非病毒游离载体及其构建方法 | |
| Fayyad-Kazan et al. | Oncolytic viruses in cancer immunotherapy: from molecular engineering to clinical translation | |
| RU2019125436A (ru) | Новый подход к иммунотерапии, нацеленной на vegfr-2 | |
| Brachtlova et al. | Unleashing the Full Potential of Oncolytic Adenoviruses against Cancer by Applying RNA Interference: The Force Awakens | |
| Kowalczyk et al. | Vaccine-induced CD8+ T cells eliminate tumors by a two-staged attack |